Missing Links? Citation Matrix | Graphs | Glossary HistCite Guide About |
MELLIN GW, 1962, NEW ENGL J MED, V267, P1184 MELLIN GW, 1962, NEW ENGL J MED, V267, P1238 LENZ W, 1961, DEUT MED WOCHENSCHR, V86, P2555 LENZ W, 1962, DEUT MED WOCHENSCHR, V87, P1232 KUNZ W, 1956, ARZNEIMITTEL-FORSCH, V6, P426 SHESKIN J, 1965, LEPROSY REV, V36, P183 WIEDEMANN HR, 1961, MED WELT, V37, P1863 BECKMANN R, 1962, ARZNEIMITTEL-FORSCH, V12, P1095 |
Nodes: 2685,
Authors: 6203,
Journals: 662,
Outer References: 16023,
Words: 3995
Collection span: 1956 - 2004
View: Overview. Sorted by journal name.
Page 2: 1 2 3 4 5 6 7 8 9
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
---|---|---|---|---|---|
301 | 15 | 31 | 449 1968 ARCHIVES OF ENVIRONMENTAL HEALTH 16(4):493-& WILLIAMS RT THALIDOMIDE - A STUDY OF BIOCHEMICAL TERATOLOGY | 9 | 20 |
302 | 0 | 0 | 743 1981 ARCHIVES OF GYNECOLOGY 232(1-4):611-612 MUHLENSTEDT D; SCHWARZ M GYNECOLOGICAL-ENDOCRINOLOGICAL STUDIES ON THALIDOMIDE-DAMAGED GIRLS | 1 | 1 |
303 | 0 | 0 | 940 1987 ARCHIVES OF GYNECOLOGY AND OBSTETRICS 242(1-4):944-945 SCHNEIDER HPG; MUHLENSTEDT D; OCHS H PUBERTY, SEXUALITY AND PARTNERSHIP IN YOUNG-PEOPLE WITH THALIDOMIDE-INDUCED DEFORMITIES | 0 | 0 |
304 | 5 | 19 | 912 1986 ARCHIVES OF INTERNAL MEDICINE 146(5):878-881 JORIZZO JL; SCHMALSTIEG FC; SOLOMON AR; CAVALLO T; TAYLOR RS; RUDLOFF HB; SCHMALSTIEG EJ; DANIELS JC THALIDOMIDE EFFECTS IN BEHCETS-SYNDROME AND PUSTULAR VASCULITIS | 25 | 57 |
305 | 8 | 10 | 1054 1992 ARCHIVES OF INTERNAL MEDICINE 152(5):1089-1090 BOUZA E; MUNOZ P; DIAZ MD; VICENTE T THALIDOMIDE IN PATIENTS WITH ACQUIRED-IMMUNODEFICIENCY-SYNDROME | 3 | 6 |
306 | 7 | 10 | 1086 1993 ARCHIVES OF INTERNAL MEDICINE 153(4):534-534 VICENTE T; ORTEGA A; MUNOZ P; DIAZ MD; BOUZA E INVITRO ACTIVITY OF THALIDOMIDE AGAINST MYCOBACTERIUM-AVIUM COMPLEX | 5 | 6 |
307 | 3 | 5 | 1814 2001 ARCHIVES OF INTERNAL MEDICINE 161(20):2502-2503 Rajkumar SV; Fonseca R; Witzig TE Complete resolution of reflex sympathetic dystrophy with thalidomide treatment | 3 | 4 |
308 | 2 | 7 | 2326 2003 ARCHIVES OF INTERNAL MEDICINE 163(12):1487-1488 Schwartzman R; Chevlen E; Bengtson K Thalidomide has activity in treating complex regional pain syndrome | 0 | 0 |
309 | 1 | 1 | 2327 2003 ARCHIVES OF INTERNAL MEDICINE 163(12):1488-1488 Rajkumar SV; Fonseca R; Witzig TE Thalidomide has activity in treating complex regional pain syndrome - Reply | 0 | 0 |
310 | 3 | 5 | 1625 2000 ARCHIVES OF OPHTHALMOLOGY 118(1):135-136 Periman LM; Sires BS Full-thickness skin grafting of eyelids in a patient with generalized morphea taking thalidomide | 1 | 1 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
311 | 2 | 10 | 271 1964 ARCHIVES OF OTOLARYNGOLOGY 80(2):136-140 DAVIGNON M; BARR B EAR ABNORMALITIES AND CRANIAL NERVE PALSIES IN THALIDOMIDE CHILDREN | 5 | 26 |
312 | 0 | 5 | 618 1976 ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY 102(7):425-427 TAKEMORI S; TANAKA Y; SUZUKI JI THALIDOMIDE ANOMALIES OF EAR | 5 | 12 |
313 | 6 | 20 | 1626 2000 ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY 126(1):89-92 Dios PD; Sopena B; Cameselle J; Butron M; Crespo M; Ocampo A Thalidomide for the treatment of acquired immunodeficiency syndrome-associated refractory oral ulcers | 2 | 3 |
314 | 3 | 14 | 641 1977 ARCHIVES OF TOXICOLOGY 37(2):165-172 JURECKA W; LASSMANN H; STOCKINGER L TERATOLOGIC-NEUROTOXIC EXAMINATION OF BIGLUMIDE (K-2004) AND THALIDOMIDE | 1 | 3 |
315 | 12 | 32 | 941 1987 ARCHIVES OF TOXICOLOGY 60(5):376-381 STERZ H; NOTHDURFT H; LEXA P; OCKENFELS H TERATOLOGIC STUDIES ON THE HIMALAYAN RABBIT - NEW ASPECTS OF THALIDOMIDE-INDUCED TERATOGENESIS | 6 | 10 |
316 | 15 | 59 | 958 1988 ARCHIVES OF TOXICOLOGY 61(3):165-179 MERKER HJ; HEGER W; SAMES K; STURJE H; NEUBERT D EMBRYOTOXIC EFFECTS OF THALIDOMIDE-DERIVATIVES IN THE NON-HUMAN PRIMATE CALLITHRIX-JACCHUS .1. EFFECTS OF 3-(1,3-DIHYDRO-1-OXO-2H-ISOINDOL-2-YL)-2,6-DIOXOPIPERIDINE (EM-12) ON SKELETAL DEVELOPMENT | 10 | 18 |
317 | 3 | 46 | 959 1988 ARCHIVES OF TOXICOLOGY 61(3):180-191 NEUBERT D; HEGER W; MERKER HJ; SAMES K; MEISTER R EMBRYOTOXIC EFFECTS OF THALIDOMIDE DERIVATIVES IN THE NON-HUMAN PRIMATE CALLITHRIX-JACCHUS .2. ELUCIDATION OF THE SUSCEPTIBLE PERIOD AND OF THE VARIABILITY OF EMBRYONIC STAGES | 8 | 21 |
318 | 3 | 11 | 960 1988 ARCHIVES OF TOXICOLOGY 62(2-3):200-204 SCHMAHL HJ; NAU H; NEUBERT D THE ENANTIOMERS OF THE TERATOGENIC THALIDOMIDE ANALOG EM-12 .1. CHIRAL INVERSION AND PLASMA PHARMACOKINETICS IN THE MARMOSET MONKEY | 8 | 18 |
319 | 5 | 15 | 961 1988 ARCHIVES OF TOXICOLOGY 62(2-3):205-208 HEGER W; KLUG S; SCHMAHL HJ; NAU H; MERKER HJ; NEUBERT D EMBRYOTOXIC EFFECTS OF THALIDOMIDE DERIVATIVES ON THE NON-HUMAN PRIMATE CALLITHRIX-JACCHUS .3. TERATOGENIC POTENCY OF THE EM-12 ENANTIOMERS | 6 | 13 |
320 | 50 | 89 | 1087 1993 ARCHIVES OF TOXICOLOGY 67(1):1-17 NEUBERT R; NOGUEIRA AC; NEUBERT D THALIDOMIDE DERIVATIVES AND THE IMMUNE-SYSTEM .1. CHANGES IN THE PATTERN OF INTEGRIN RECEPTORS AND OTHER SURFACE-MARKERS ON LYMPHOCYTE-T SUBPOPULATIONS OF MARMOSET BLOOD | 40 | 49 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
321 | 4 | 10 | 1119 1994 ARCHIVES OF TOXICOLOGY 68(3):203-205 KLUG S; FELIES A; STURJE H; NOGUEIRA AC; NEUBERT R; FRANKUS E EMBRYOTOXIC EFFECTS OF THALIDOMIDE DERIVATIVES IN THE NONHUMAN PRIMATE CALLITHRIX-JACCHUS .5. LACK OF TERATOGENIC EFFECTS OF PHTHALIMIDOPHTHALIMIDE | 4 | 7 |
322 | 10 | 22 | 1240 1996 ARCHIVES OF TOXICOLOGY 70(11):749-756 Schmahl HJ; Dencker L; Plum C; Chahoud I; Nau H Stereoselective distribution of the teratogenic thalidomide analogue EM12 in the early embryo of marmoset monkey, Wistar rat and NMRI mouse | 3 | 7 |
323 | 18 | 27 | 2037 2002 ARCHIVOS DE BRONCONEUMOLOGIA 38(10):492-494 Valero FC; Gonzalez VB Lung toxicity due to thalidomide | 1 | 1 |
324 | 0 | 4 | 2328 2003 ARCHIVOS DE BRONCONEUMOLOGIA 39(5):240-240 Garcia BD; Gafas AD; Alvarez MJF Lung toxicity due to thalidomide | 0 | 0 |
325 | 1 | 5 | 2329 2003 ARCHIVOS DE BRONCONEUMOLOGIA 39(6):286-286 Valero FC Lung toxicity due to thalidomide | 0 | 0 |
326 | 7 | 18 | 875 1985 ARCHIVOS DE INVESTIGACION MEDICA 16(2):139-143 AVALOSDIAZ E; GUZMANENRIQUEZ L; LOPEZROBLES E; HERRERAESPARZA R INHIBITORY EFFECT OF ENDOCYTOSIS IN POLIMORPHONUCLEAR CELLS CAUSED BY THALIDOMIDE | 0 | 0 |
327 | 11 | 36 | 2582 2004 ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY 24(5):885-891 Park SJ; Kim HS; Yang HM; Park KW; Youn SW; Jeon SI; Kim DH; Koo BK; Chae IH; Choi DJ; Oh BH; Lee MM; Park YB Thalidomide as a potent inhibitor of neointimal hyperplasia after balloon injury in rat carotid artery | 0 | 0 |
328 | 8 | 14 | 2038 2002 ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH 47(3):249-254 Huang F; Gu JR; Zhao W; Zhu J; Zhang JL; Yu DTY One-year open-label trial of thalidomide in ankylosing spondylitis | 3 | 9 |
329 | 5 | 11 | 2583 2004 ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH 51(3):505-506 Pillemer SR; Leakan RA; Sankar V; Manny J; Baum BJ; Smith J; Chaudhry U; Fox PC; Radfar L; Ligier S; Brennan MT Prominent adverse effects of thalidomide in primary Sjogren's syndrome | 0 | 0 |
330 | 12 | 24 | 844 1984 ARTHRITIS AND RHEUMATISM 27(10):1118-1121 GUTIERREZRODRIGUEZ O THALIDOMIDE - A PROMISING NEW TREATMENT FOR RHEUMATOID-ARTHRITIS | 46 | 55 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
331 | 2 | 3 | 876 1985 ARTHRITIS AND RHEUMATISM 28(7):836-836 MIYACHI Y A POSSIBLE MECHANISM OF ACTION OF THALIDOMIDE ON RHEUMATOID-ARTHRITIS | 5 | 5 |
332 | 8 | 8 | 913 1986 ARTHRITIS AND RHEUMATISM 29(10):1296-1296 SHEEHAN NJ THALIDOMIDE NEUROTOXICITY AND RHEUMATOID-ARTHRITIS | 2 | 2 |
333 | 5 | 5 | 962 1988 ARTHRITIS AND RHEUMATISM 31(1):145-146 GUTIERREZRODRIGUEZ O; STARUSTABACAL P; GUTIERREZMONTES O THALIDOMIDE-INDUCED NEUROPATHY IN RHEUMATOID-ARTHRITIS PATIENTS | 2 | 4 |
334 | 0 | 0 | 1172 1995 ARTHRITIS AND RHEUMATISM 38(6):R10-R10 OLIVER SJ; CHENG TP; BANQUERIGO ML; BRAHN E THALIDOMIDE ANALOGS SUPPRESS RAT COLLAGEN ARTHRITIS | 1 | 2 |
335 | 0 | 0 | 1173 1995 ARTHRITIS AND RHEUMATISM 38(9):769-769 SCOVILLE CD OPEN TRIAL OF THALIDOMIDE IN THE TREATMENT OF RHEUMATOID-ARTHRITIS | 0 | 0 |
336 | 0 | 0 | 1241 1996 ARTHRITIS AND RHEUMATISM 39(9):1352-1352 Stevens RJ; Andujar C; Edwards C; Ames PRJ; Barwick AR; Khamashta MA; Hughes GRV Thalidomide in the treatment of cutaneous manifestations of lupus erythematosus. | 0 | 1 |
337 | 0 | 0 | 1242 1996 ARTHRITIS AND RHEUMATISM 39(9):1353-1353 Sato EI; Assis LSS; Furtado R Long-term thalidomide therapy for cutaneous lesions of systemic lupus erythematosus (SLE) | 0 | 0 |
338 | 0 | 0 | 1243 1996 ARTHRITIS AND RHEUMATISM 39(9):1524-1524 Lee S; Klausner J; Oliver S; Kaplan G; McCullagh E Treatment of rheumatoid arthritis (RA) with thalidomide | 1 | 1 |
339 | 0 | 0 | 1313 1997 ARTHRITIS AND RHEUMATISM 40(9):210-210 Hamuryudan V; Mat C; Saip S; Ozyazgan Y; Siva A; Yurdakul S; Zwingenberger K; Yazici H Randomised and placebo controlled trial of two different doses of thalidomide in Behcet's syndrome | 0 | 0 |
340 | 0 | 0 | 1401 1998 ARTHRITIS AND RHEUMATISM 41(9):S60-S60 Scoville CD Open trial using methotrexate and thalidomide in the treatment of rheumatoid arthritis. | 2 | 2 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
341 | 0 | 0 | 1402 1998 ARTHRITIS AND RHEUMATISM 41(9):S98-S98 Oliver SJ; Freeman SL; Kaplan G Thalidomide and analog CC1089 in rat adjuvant arthritis. | 0 | 0 |
342 | 0 | 0 | 1403 1998 ARTHRITIS AND RHEUMATISM 41(9):S108-S108 Ordi-Ros J; Cortes F; Martinez N; Montse M; De Torres I; Vilardell M Thalidomide induces amenorrhea in patients with lupus disease. | 0 | 0 |
343 | 7 | 13 | 1404 1998 ARTHRITIS AND RHEUMATISM 41(12):2273-2275 Ordi J; Cortes F; Martinez N; Mauri M; De Torres I; Vilardell M Thalidomide induces amenorrhea in patients with lupus disease | 12 | 19 |
344 | 3 | 8 | 1490 1999 ARTHRITIS AND RHEUMATISM 42(3):580-581 Breban M; Gombert B; Amor B; Dougados M Efficacy of thalidomide in the treatment of refractory ankylosing spondylitis | 16 | 53 |
345 | 0 | 0 | 1491 1999 ARTHRITIS AND RHEUMATISM 42(9):S91-S91 Connolly JE; Rigby WFC Thalidomide inhibits LPS induced activation of p38 and JNK stress activated kinase pathways. | 0 | 0 |
346 | 0 | 0 | 1492 1999 ARTHRITIS AND RHEUMATISM 42(9):S187-S187 Oliver SJ; Moreira A; Kaplan G Reduced fibrosis and normalization of skin structure in scleroderma patients treated with thalidomide. | 1 | 5 |
347 | 0 | 0 | 1493 1999 ARTHRITIS AND RHEUMATISM 42(9):S276-S276 Oliver SJ; Moreira A; Ozawa M; Krueger JG; Kaplan G Beneficial effects of thalidomide in sarcoidosis are associated with an enhanced Th1-type immune response | 0 | 0 |
348 | 0 | 0 | 1494 1999 ARTHRITIS AND RHEUMATISM 42(9):S373-S373 El Hassani S; Dougados M; Gombert B; Amor B; Breban M Treatment of severe retractory spondylarthopathy (SPA) with thalidomide: Results of an open study. | 2 | 6 |
349 | 0 | 0 | 1495 1999 ARTHRITIS AND RHEUMATISM 42(10):2259-2260 Gompel A; Frances C; Piette JC; Blanc AS; Cordoliani F; Piette AM Ovarian failure with thalidomide treatment in complex aphthosis: comment on the concise communication by Ordi et al | 7 | 8 |
350 | 0 | 0 | 1496 1999 ARTHRITIS AND RHEUMATISM 42(10):2260-2260 Ordi J; Cortes F; Balada E; Mauri M; Vilardell M Ovarian failure with thalidomide treatment in complex aphthosis: comment on the concise communication by Ordi et al - Reply | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
351 | 0 | 0 | 1627 2000 ARTHRITIS AND RHEUMATISM 43(9):S117-S117 Lowe D; Kredich DW; Schanberg LE Thalidomide: An effective and safe agent for the treatment of pediatric mixed connective tissue disease. | 0 | 0 |
352 | 0 | 0 | 1628 2000 ARTHRITIS AND RHEUMATISM 43(9):S396-S396 Huang F; Gu J; Braun J; Sieper J; Yu DT Identifying the targets of thalidomide and anti-TNF alpha antibody treatments in ankylosing spondylitis (AS). | 2 | 5 |
353 | 0 | 0 | 1815 2001 ARTHRITIS AND RHEUMATISM 44(9):S125-S125 Barthel HR Successful treatment of Weber Christian disease (WCD) with thalidomide in a patient failing multiple other medical therapies | 0 | 0 |
354 | 0 | 0 | 1816 2001 ARTHRITIS AND RHEUMATISM 44(9):S272-S272 Lehman TJ; Striegel KH; Onel KB Thalidomide therapy for corticosteroid dependent systemic onset juvenile rheumatoid arthritis | 0 | 1 |
355 | 0 | 0 | 1817 2001 ARTHRITIS AND RHEUMATISM 44(9):S275-S275 Huang F; Gu JR; Zhao W; Zhu J; Zhang JL; Yu DTY Therapeutic effect and molecular targets of thalidomide in refractory ankylosing spondylitis (AS). | 0 | 2 |
356 | 0 | 0 | 1818 2001 ARTHRITIS AND RHEUMATISM 44(9):S280-S280 Cuadrado MJ; Smith E; Gordon P; Karim Y; Khamashta MA; Hughes GRV Thalidomide: Efficacy and safety in 30 patients with lupus and skin involvement. | 0 | 0 |
357 | 6 | 6 | 1819 2001 ARTHRITIS AND RHEUMATISM 44(10):2456-2457 Lee L; Lawford R; McNeil HP The efficacy of thalidomide in severe refractory seronegative spondylarthropathy: comment on the letter by Breban et al | 2 | 5 |
358 | 1 | 4 | 1820 2001 ARTHRITIS AND RHEUMATISM 44(10):2457-2458 Breban M; Dougados M The efficacy of thalidomide in severe refractory seronegative spondylarthropathy: Reply | 2 | 5 |
359 | 0 | 0 | 2039 2002 ARTHRITIS AND RHEUMATISM 46(9):S290-S290 Cuadrado MJ; Karim Y; Sanna G; Smith E; Khamashta MA; Hughes GRV Thalidomide in lupus: Efficacy and toxicity are not dose-dependent. | 0 | 0 |
360 | 0 | 0 | 2040 2002 ARTHRITIS AND RHEUMATISM 46(9):S480-S481 Schwartz KH; Agle LMA; Lehman TJA Thalidomide therapy of systemic onset JIA: Continued success. | 0 | 2 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
361 | 0 | 0 | 2330 2003 ARTHRITIS AND RHEUMATISM 48(9):S92-S92 Schechter SJ; Sundel R; Oliveira SK; Huttenlocher A; Onel K; Lehman TJA Thalidomide for severe systemic onset JIA. | 0 | 0 |
362 | 0 | 0 | 2331 2003 ARTHRITIS AND RHEUMATISM 48(9):S587-S587 Doria A; Briani C; Zara G; Rondinone R; Ermani M; Della Libera S; Ghirardello A; Zampieri S; Tedesco S Prospective study on thalidomide-induced peripheral neuropathy in SLE. | 0 | 0 |
363 | 0 | 0 | 2332 2003 ARTHRITIS AND RHEUMATISM 48(9):S588-S589 Vazquez-Cobian LB; Onel KB; Lehman TJA Thalidomide in systemic lupus erythematosus. | 0 | 0 |
364 | 0 | 0 | 2333 2003 ARTHRITIS AND RHEUMATISM 48(9):S617-S617 Efthimiou P; Rosenkranz ME; Mackenzie R; Adler R; Paget SA IVIG and thalidomide combination is an effective novel therapy for scleromyxedema. | 0 | 0 |
365 | 0 | 189 1963 ARZNEIMITTEL-FORSCHUNG 13:185-191 BECKMANN R The behavior of thalidomide in the human and animal organism. part 2. | 35 | 47 | |
366 | 2 | 21 | 313 1965 ARZNEIMITTEL-FORSCHUNG 15(5):508-& CHAMPYHA.S ACTION DE LIMIDAZOLE SUR LES PREMIERS METABOLITES DE LA THALIDOMIDE - ETUDE DE LA SCISSION DU NOYAU PHTALIMIDE | 0 | 10 |
367 | 0 | 0 | 418 1967 ARZNEIMITTEL-FORSCHUNG 17(5):646-& BUELENS I TREATMENT WITH THALIDOMIDE OF AN ASTROCYTOMA OF SECOND DEGREE (N-PHTHALYGLUTAMIC ACID IMIDE) | 2 | 3 |
368 | 1 | 33 | 419 1967 ARZNEIMITTEL-FORSCHUNG 17(9):1155-& CHAMPYHA.S CONJUGATED ACTION OF 2 NUCLEI OF THALIDOMIDE ON IMIDAZOLINE COMPOUNDS - HISTAMINE AND PURINE BASES | 0 | 4 |
369 | 6 | 27 | 420 1967 ARZNEIMITTEL-FORSCHUNG 17(11):1360-& GLEISS J GROWTH OF EMBRYOS OF SINAPIS ALBA INHIBITED BY N-PHTHALYGLUTAMIC ACID IMIDE(THALIDOMIDE) . NA-PHENYLETHYLBARBITURIC ACID (PHENOBARBITAL-NA) AND ALPHA-ETHYL-ALPHA-PHENYLGLUTARIMIDE)GLUTETHIMIDE) | 1 | 12 |
370 | 4 | 22 | 450 1968 ARZNEIMITTEL-FORSCHUNG 18(6):661-& BRODE E EXPERIMENTAL STUDIES ON CYCLIC IMIDES .I. INFLUENCE OF THALIDOMIDE ON PITUITARY-ADRENAL AXIS | 1 | 2 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
371 | 6 | 18 | 451 1968 ARZNEIMITTEL-FORSCHUNG 18(10):1313-& BRODE E EXPERIMENTAL STUDIES ON CYCLIC IMIDES .4. CLEAVING OF PHTHALIMIDE RING IN THALIDOMIDE BY AMINES | 6 | 10 |
372 | 16 | 29 | 477 1969 ARZNEIMITTEL-FORSCHUNG 19(2):167-& STOCKING.L; KOCH H TERATOLOGY STUDY ON A NEW COMPOUND (K-2004) WITH SEDATIVE-HYPNOTIC ACTIVITY AND STRUCTURALLY RELATED TO THALIDOMIDE | 0 | 20 |
373 | 4 | 41 | 478 1969 ARZNEIMITTEL-FORSCHUNG 19(9):1544-& KOCH H INHIBITOR EFFECT OF THALIDOMIDE AND SEVERAL ANALEPTIC DRUGS ON GERMINATION AND EMBRYONIC GROWTH OF LEPIDIUM SATIVUM L | 0 | 8 |
374 | 3 | 11 | 515 1971 ARZNEIMITTEL-FORSCHUNG 21(12):2022-& KOCH H; STOCKING.L TERATOLOGY STUDY ON 3-(1,4-ENDOXO-CYCLOHEXANE-2-EXO-3-EXO-DICARBOXIMIDO)-PIPERIDINE-2,6-DIONE (K-2604), ANOTHER COMPOUND WITH SEDATIVE-HYPNOTIC ACTIVITY AND STRUCTURALLY RELATED TO THALIDOMIDE | 2 | 4 |
375 | 0 | 13 | 1 1956 ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH 6(8):426-430 KUNZ W; KELLER H; MUCKTER H N-PHTHALYL-GLUTAMINIC IMIDE | 40 | 76 |
376 | 9 | 21 | 590 1974 ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH 24(10):1616-1619 KOHLER F; KOCH H TERATOLOGY STUDY ON THALIDOMIDE-LIKE COMPOUNDS K-2004 AND K-2604 IN MOUSE AND RAT | 9 | 21 |
377 | 1 | 18 | 664 1978 ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH 28-2(9):1567-1570 SONNENBICHLER J; LULING L STUDIES ON POSSIBLE INTERACTIONS OF THALIDOMIDE AND GENETIC MATERIAL FROM CHICKEN EMBRYOS | 0 | 0 |
378 | 5 | 36 | 744 1981 ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH 31-1(2):315-320 FLOHE L; DRAEGER E; FRANKUS E; GRAUDUMS I; GUNZLER WA; HELM FC; KUUTTISAVOLAINEN ER STUDIES ON THE HYPOTHETICAL RELATIONSHIP OF THALIDOMIDE-INDUCED EMBRYOPATHY AND COLLAGEN BIOSYNTHESIS | 0 | 10 |
379 | 13 | 39 | 745 1981 ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH 31-1(6):941-949 HELM FC; FRANKUS E; FRIDERICHS E; GRAUDUMS I; FLOHE L COMPARATIVE TERATOLOGICAL INVESTIGATION OF COMPOUNDS STRUCTURALLY AND PHARMACOLOGICALLY RELATED TO THALIDOMIDE | 0 | 54 |
380 | 1 | 22 | 777 1982 ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH 32-1(6):613-620 FRIDERICHS E STUDIES ON THE CNS ACTIVITY PROFILE OF THALIDOMIDE ANALOGS | 0 | 8 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
381 | 0 | 2 | 778 1982 ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH 32-2(8):898-898 FRANKUS E; FRIDERICHS E; GRAUDUMS I; HELM FC CHEMICAL-STRUCTURE, TERATOGENICITY AND PHARMACOLOGICAL ACTIVITY OF THALIDOMIDE RELATED-COMPOUNDS | 0 | 1 |
382 | 15 | 36 | 914 1986 ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH 36-2(7):1138-1141 GUNZLER V; HANAUSKEABEL HM; TSCHANK G; SCHULTEWISSERMANN H IMMUNOLOGICAL EFFECTS OF THALIDOMIDE - INACTIVITY OF THE DRUG AND SEVERAL OF ITS HYDROLYSIS PRODUCTS IN MONONUCLEOCYTE PROLIFERATION TESTS | 0 | 10 |
383 | 7 | 27 | 1005 1990 ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH 40-1(1):32-36 BUCH HP; OMLOR G; KNABE J STEREOSELECTIVE DIFFERENCES OF THE CNS-DEPRESSANT ACTIVITY IN A HOMOLOGOUS SERIES OF 3-ALKYL-THALIDOMIDE ANALOGS | 0 | 5 |
384 | 0 | 0 | 1405 1998 ASM NEWS 64(10):557-558 Fox JL Thalidomide approved for treating leprosy | 1 | 1 |
385 | 0 | 0 | 2334 2003 ATHEROSCLEROSIS SUPPLEMENTS 4(2):28-28 Park SJ Thalidomide as a potent inhibitor of neointimal hyperplasia after balloon injury in rat carotid artery | 0 | 0 |
386 | 0 | 0 | 691 1979 ATLANTIC 244(1):59-59 PHILLIPS M 'THALIDOMIDE' | 0 | 0 |
387 | 0 | 0 | 801 1983 AUSTRALIAN PAEDIATRIC JOURNAL 19(3):198-198 NORTH K; MCCREDIE J THALIDOMIDE DEFORMITIES AND THEIR NERVE SUPPLY | 0 | 0 |
388 | 0 | 0 | 877 1985 AUSTRALIAN PAEDIATRIC JOURNAL 21(4):295-295 DUNLOP GM; MCCREDIE J QUANTITATIVE NEUROLOGICAL CHANGES IN THALIDOMIDE EMBRYOPATHY | 0 | 0 |
389 | 5 | 20 | 746 1981 BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 98(4):1029-1034 BRAUN AG; DAILEY JP THALIDOMIDE METABOLITE INHIBITS TUMOR-CELL ATTACHMENT TO CONCANAVALIN A COATED SURFACES | 6 | 16 |
390 | 6 | 11 | 1120 1994 BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 199(2):455-460 NISHIMURA K; HASHIMOTO Y; IWASAKI S ENHANCEMENT OF PHORBOL ESTER-INDUCED PRODUCTION OF TUMOR-NECROSIS-FACTOR-ALPHA BY THALIDOMIDE | 26 | 43 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
391 | 5 | 21 | 1244 1996 BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 224(2):426-430 Miyachi H; Azuma A; Hioki E; Iwasaki S; Kobayashi Y; Hashimoto Y Inducer-specific bidirectional regulation by thalidomide and phenylphthalimides of tumor necrosis factor-alpha production | 15 | 25 |
392 | 7 | 14 | 1245 1996 BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 226(2):439-444 Miyachi H; Azuma A; Hioki E; Iwasaki S; Kobayashi Y; Hashimoto Y Cell type-/inducer-specific bidirectional regulation by thalidomide and phenylphthalimides of tumor necrosis factor-alpha production and its enantio-dependence | 13 | 20 |
393 | 4 | 4 | 272 1964 BIOCHEMICAL JOURNAL 90(1):P5-& FABRO S; SCHUMACHER H; STAGG BL; SMITH RL; WILLIAMS RT BIOLOGICAL ACTIVITY OF THALIDOMIDE METABOLITES | 11 | 15 |
394 | 0 | 1 | 314 1965 BIOCHEMICAL JOURNAL 97(2):P14-& FABRO S; SMITH RL; WILLIAMS RT PERSISTENCE OF MATERNALLY ADMINISTERED [14C] THALIDOMIDE IN RABBIT EMBRYO | 1 | 2 |
395 | 2 | 5 | 421 1967 BIOCHEMICAL JOURNAL 103(1):P26-& FABRO S; HAGUE D; SMITH RL FATE OF [14C]THALIDOMIDE IN PREGNANT HAMSTER | 3 | 3 |
396 | 6 | 15 | 422 1967 BIOCHEMICAL JOURNAL 104(2):565-& FABRO S; SMITH RL; WILLIAMS RT FATE OF [14C]THALIDOMIDE IN PREGNANT RABBIT | 17 | 20 |
397 | 3 | 9 | 423 1967 BIOCHEMICAL JOURNAL 104(2):570-& FABRO S; SMITH RL; WILLIAMS RT FATE OF HYDROLYSIS PRODUCTS OF THALIDOMIDE IN PREGNANT RABBIT | 14 | 17 |
398 | 0 | 0 | 190 1963 BIOCHEMICAL PHARMACOLOGY 12:47-& SOMERS GF THALIDOMIDE AND CONGENITAL MALFORMATIONS | 0 | 2 |
399 | 0 | 1 | 191 1963 BIOCHEMICAL PHARMACOLOGY 12:246-& VASILESCU V; CIURES A; DIMOFTAC.C; TRUTIA E DES RESULTATS CONCERNANT LACTION DE LA THALIDOMIDE SUR LES ACIDES NUCLEIQUES | 0 | 0 |
400 | 0 | 0 | 192 1963 BIOCHEMICAL PHARMACOLOGY 12:246-& SOMERS GF THALIDOMIDE AND CONGENITAL MALFORMATIONS | 0 | 2 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
401 | 14 | 21 | 273 1964 BIOCHEMICAL PHARMACOLOGY 13(6):940-& CHAUDHARY KD; LEMONDE A EFFECT OF THALIDOMIDE ON TRIBOLIUM CONFUSUM DUVAL | 2 | 4 |
402 | 19 | 58 | 274 1964 BIOCHEMICAL PHARMACOLOGY 13(11):1489-& TOIVANEN A; TOIVANEN P; MANTYJAR.R; MARKKANEN T MICROBIOLOGICALLY DETERMINED PANTOTHENIC ACID + NICOTINIC ACID CONTENT OF CHICK EMBRYOS AFTER TREATMENT WITH THALIDOMIDE + OF RAT FETUSES NEWBORNS + PLACENTAS FROM MOTHERS TREATED WITH THALIDOMIDE | 2 | 4 |
403 | 7 | 17 | 315 1965 BIOCHEMICAL PHARMACOLOGY 14(5):893-& GERSHBEI.LL EFFECT OF THALIDOMIDE ON RAT LIVER REGENERATION AND DIAPHRAGM CARBOHYDRATE METABOLISM | 0 | 10 |
404 | 9 | 24 | 845 1984 BIOCHEMICAL PHARMACOLOGY 33(9):1471-1477 BRAUN AG; WEINREB SL TERATOGEN METABOLISM - ACTIVATION OF THALIDOMIDE AND THALIDOMIDE ANALOGS TO PRODUCTS THAT INHIBIT THE ATTACHMENT OF CELLS TO CONCANAVALIN A COATED PLASTIC SURFACES | 15 | 24 |
405 | 14 | 27 | 1314 1997 BIOCHEMICAL PHARMACOLOGY 53(10):1553-1557 Nicolai S; Sies H; Stahl W Stimulation of gap junctional intercellular communication by thalidomide and thalidomide analogs in human skin fibroblasts | 6 | 11 |
406 | 13 | 27 | 1406 1998 BIOCHEMICAL PHARMACOLOGY 55(11):1827-1834 Bauer KS; Dixon SC; Figg WD Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent | 80 | 120 |
407 | 36 | 174 | 1629 2000 BIOCHEMICAL PHARMACOLOGY 59(12):1489-1499 Stephens TD; Bunde CJW; Fillmore BJ Mechanism of action in thalidomide teratogenesis | 24 | 36 |
408 | 3 | 23 | 1821 2001 BIOCHEMICAL PHARMACOLOGY 62(8):1081-1086 Onat D; Stahl W; Sies H Stimulation of gap junctional intercellular communication by thalidomide and thalidomide analogs in human fetal skin fibroblasts (HFFF2) and in rat liver epithelial cells (WB-F344) | 2 | 3 |
409 | 6 | 11 | 988 1989 BIOCHEMICAL SOCIETY TRANSACTIONS 17(1):114-115 LYNE C; GOWER DB RADIAL THIN-LAYER CHROMATOGRAPHIC AUTORADIOGRAPHIC SCANS OF STEROID-METABOLISM IN THE PRESENCE OF THALIDOMIDE | 0 | 1 |
410 | 55 | 79 | 1497 1999 BIODRUGS 11(6):409-416 Powell RJ Thalidomide - Current uses | 1 | 2 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
411 | 83 | 113 | 1630 2000 BIODRUGS 13(4):255-265 Kontogiannis V; Powell RJ Use of thalidomide in dermatological indications | 0 | 0 |
412 | 52 | 73 | 1822 2001 BIODRUGS 15(3):163-172 Singhal S; Mehta J Thalidomide in cancer - Potential uses and limitations | 12 | 16 |
413 | 115 | 191 | 1823 2001 BIODRUGS 15(10):681-703 Meierhofer C; Dunzendorfer S; Wiedermann CJ Theoretical basis for the activity of thalidomide | 6 | 12 |
414 | 0 | 0 | 2335 2003 BIOFUTUR (238):42-43 Knoll M The return of thalidomide | 0 | 0 |
415 | 18 | 32 | 1121 1994 BIOGENIC AMINES 10(6):543-554 AUDIT CO THALIDOMIDE-INDUCED POLYAMINE ACYLATION - A NEW INSIGHT INTO THE ACYLATION MECHANISM | 3 | 3 |
416 | 8 | 65 | 1246 1996 BIOGENIC AMINES 12(4):305-326 Audit CO Specific functions of polyamines: Actin assembly, cytokinesis induction, targets for thalidomide activity, nitrogen sources for marine ecosystems | 1 | 3 |
417 | 7 | 23 | 1174 1995 BIOLOGICAL & PHARMACEUTICAL BULLETIN 18(9):1228-1233 SASAKI K; SHIBATA Y; HASHIMOTO Y; IWASAKI S BENZYLPHTHALIMIDES AND PHENETHYLPHTHALIMIDES WITH THALIDOMIDE-LIKE ACTIVITY ON THE PRODUCTION OF TUMOR-NECROSIS-FACTOR-ALPHA | 7 | 18 |
418 | 5 | 15 | 1407 1998 BIOLOGICAL & PHARMACEUTICAL BULLETIN 21(6):638-640 Ishikawa M; Kanno S; Takayanagi M; Takayanagi Y; Sasaki K Thalidomide promotes the release of tumor necrosis factor-alpha (TNF-alpha) and lethality by lipopolysaccharide in mice | 5 | 6 |
419 | 8 | 26 | 1498 1999 BIOLOGICAL & PHARMACEUTICAL BULLETIN 22(2):224-226 Shimazawa R; Miyachi H; Takayama H; Kuroda K; Kato F; Kato M; Hashimoto Y Antiangiogenic activity of tumor necrosis factor-alpha production regulators derived from thalidomide | 10 | 16 |
420 | 39 | 71 | 2041 2002 BIOLOGICAL & PHARMACEUTICAL BULLETIN 25(5):597-604 Marks MG; Shi JD; Fry MO; Xiao ZL; Trzyna M; Pokala V; Ihnat MA; Li PK Effects of putative hydroxylated thalidomide metabolites on blood vessel density in the chorioallantoic membrane (CAM) assay and on tumor and endothelial cell proliferation | 6 | 9 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
421 | 0 | 0 | 193 1963 BIOLOGICAL BULLETIN 125(2):373-& BURKE JA; SPEAR JF SOME MORPHOLOGICAL AND PHYSIOLOGICAL EFFECTS OF THALIDOMIDE ON EMBRYOS OF FUNDULUS HETEROCLITUS | 0 | 0 |
422 | 4 | 18 | 1824 2001 BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION 7(5):265-273 Arora M; Wagner JE; Davies SM; Blazar BR; Defor T; Enright H; Miller WF; Weisdorf DJ Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease | 8 | 15 |
423 | 0 | 0 | 2584 2004 BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION 10(2):73-73 Grosskreutz CL; Egan R; Scigliano E; Fruchtman SM; Isola LM Thalidomide maintenance after autologous stem cell transplantation for multiple myeloma | 0 | 0 |
424 | 1 | 33 | 1825 2001 BIOMEDICAL CHROMATOGRAPHY 15(3):202-206 Duval R; Leveque H; Prigent Y; Aboul-Enein HY Enantioseparation of aminoglutethimide and thalidomide by high performance liquid chromatography or supercritical fluid chromatography on mono-2 and mono-6-O-pentenyl-beta-cyclodextrin-based chiral stationary phases | 1 | 4 |
425 | 15 | 23 | 989 1989 BIOMEDICINE & PHARMACOTHERAPY 43(9):693-697 MCCARTHY DM; KANFER EJ; BARRETT AJ THALIDOMIDE FOR THE THERAPY OF GRAFT-VERSUS-HOST DISEASE FOLLOWING ALLOGENEIC BONE-MARROW TRANSPLANTATION | 15 | 17 |
426 | 28 | 39 | 1006 1990 BIOMEDICINE & PHARMACOTHERAPY 44(4):199-204 HENEY D; BAILEY CC; LEWIS IJ THALIDOMIDE IN THE TREATMENT OF GRAFT-VERSUS-HOST DISEASE | 12 | 14 |
427 | 12 | 26 | 2042 2002 BIOMEDICINE & PHARMACOTHERAPY 56(1):1-3 Mathe G Thalidomide, a drug which may protect the organism against some aggressive effects of the immunologic system | 0 | 0 |
428 | 54 | 61 | 2043 2002 BIOMEDICINE & PHARMACOTHERAPY 56(1):4-12 Singhal S; Mehta J Thalidomide in cancer | 16 | 20 |
429 | 20 | 42 | 2044 2002 BIOMEDICINE & PHARMACOTHERAPY 56(1):13-19 Sampaio EP; Hernandez MO; Carvalho DS; Sarno EN Management of erythema nodosum leprosum by thalidomide: thalidomide analogues inhibit M-leprae-induced TNF alpha production in vitro | 5 | 6 |
430 | 15 | 82 | 2045 2002 BIOMEDICINE & PHARMACOTHERAPY 56(1):20-30 Zorat F; Pozzato G Thalidomide in myelodysplastic syndromes | 3 | 3 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
431 | 19 | 48 | 2046 2002 BIOMEDICINE & PHARMACOTHERAPY 56(1):31-35 Shek LPC; Lim DLC Thalidomide in Behcet's disease | 7 | 10 |
432 | 56 | 93 | 2047 2002 BIOMEDICINE & PHARMACOTHERAPY 56(3):115-128 Richardson P; Hideshima T; Anderson K Thalidomide in multiple myeloma | 5 | 6 |
433 | 32 | 45 | 2048 2002 BIOMEDICINE & PHARMACOTHERAPY 56(4):194-199 Ng SSW; Brown M; Figg WD Thalidomide, an antiangiogenic agent with clinical activity in cancer | 5 | 6 |
434 | 14 | 32 | 1826 2001 BIOORGANIC & MEDICINAL CHEMISTRY 9(4):1059-1065 Gutschow M; Hecker T; Thiele A; Hauschildt S; Eger K Aza analogues of thalidomide: Synthesis and evaluation as inhibitors of tumor necrosis factor-alpha production in vitro | 3 | 8 |
435 | 17 | 41 | 1827 2001 BIOORGANIC & MEDICINAL CHEMISTRY 9(5):1279-1291 Hess S; Akermann MA; Wnendt S; Zwingerberger K; Eger K Synthesis and immunological activity of water-soluble thalidomide prodrugs | 2 | 4 |
436 | 30 | 91 | 2049 2002 BIOORGANIC & MEDICINAL CHEMISTRY 10(3):461-479 Hashimoto Y Structural development of biological response modifiers based on thalidomide | 7 | 14 |
437 | 4 | 33 | 2050 2002 BIOORGANIC & MEDICINAL CHEMISTRY 10(9):3067-3073 Lima LM; Castro P; Machado AL; Fraga CAM; Lugnier C; de Moraes VLG; Barreiro EJ Synthesis and anti-inflammatory activity of phthalimide derivatives, designed as new thalidomide analogues | 2 | 6 |
438 | 12 | 43 | 2585 2004 BIOORGANIC & MEDICINAL CHEMISTRY 12(2):327-336 Capitosti SM; Hansen TP; Brown ML Thalidomide analogues demonstrate dual inhibition of both angiogenesis and prostate cancer | 0 | 0 |
439 | 7 | 20 | 1408 1998 BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 8(9):1071-1076 Niwayama S; Loh C; Turk BE; Liu JO; Miyachi H; Hashimoto Y Enhanced potency of perfluorinated thalidomide derivatives for inhibition of LPS-induced tumor necrosis factor-alpha production is associated with a change of mechanism of action | 8 | 10 |
440 | 4 | 13 | 1409 1998 BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 8(19):2669-2674 Muller GW; Shire MG; Wong LM; Corral LG; Patterson RT; Chen YX; Stirling DI Thalidomide analogs and PDE4 inhibition | 20 | 31 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
441 | 8 | 30 | 2051 2002 BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 12(7):1043-1046 Noguchi T; Shimazawa R; Nagasawa K; Hashimoto Y Thalidomide and its analogues as cyclooxygenase inhibitors | 9 | 11 |
442 | 13 | 26 | 2336 2003 BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 13(20):3415-3417 Man HW; Corral LG; Stirling DI; Muller GW alpha-fluoro-substituted thalidomide analogues | 1 | 1 |
443 | 14 | 35 | 2586 2004 BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 14(2):421-425 Perino S; Contino-Pepin C; Satchi-Fainaro R; Butterfield C; Pucci B Inhibition of angiogenesis by THAM-derived cotelomers endowed with thalidomide moieties | 0 | 0 |
444 | 6 | 31 | 2587 2004 BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 14(16):4141-4145 Noguchi T; Sano H; Shimazawa R; Tanatani A; Miyachi H; Hashimoto Y Phenylhomophthalimide-type NOS inhibitors derived from thalidomide | 0 | 0 |
445 | 15 | 33 | 1631 2000 BIOPHARMACEUTICS & DRUG DISPOSITION 21(1):33-40 Teo SK; Scheffler MR; Kook KA; Tracewell WG; Colburn WA; Stirling DI; Thomas SD Effect of a high-fat meal on thalidomide pharmacokinetics and the relative bioavailability of oral formulations in healthy men and women | 6 | 6 |
446 | 0 | 0 | 1410 1998 BIOTECHNOLOGY LAW REPORT 17(3):361-362 [Anon] FDA grants orphan drug designation to thalidomide as treatment for primary brain cancers | 0 | 0 |
447 | 0 | 0 | 1411 1998 BIOTECHNOLOGY LAW REPORT 17(5):596-597 [Anon] Notorious teratogen wins FDA approval for leprosy - Thalidomide will be most tightly regulated drug ever | 0 | 0 |
448 | 0 | 0 | 2337 2003 BIOTECHNOLOGY LAW REPORT 22(2):120-120 [Anon] Celgene, EntreMed agree to license for thalidomide analog - Companies will drop their infringement suits | 0 | 0 |
449 | 27 | 47 | 2588 2004 BIRTH DEFECTS RESEARCH PART B-DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY 71(1):1-16 Teo SK; Denny KH; Stirling DI; Thomas SD; Morseth SL; Hoberman AM Effects of thalidomide on reproductive function and early embryonic development in male and female New Zealand white rabbits | 0 | 0 |
450 | 11 | 19 | 2052 2002 BJU INTERNATIONAL 89(6):591-595 Douglas ML; Reid JL; Hii SI; Jonsson JR; Nicol DL Renal cell carcinoma may adapt to and overcome anti-angiogenic intervention with thalidomide | 1 | 4 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
451 | 0 | 0 | 1088 1993 BLOOD 82(10):A421-A421 VOGELSANG GB; COLVIN OM; ALTOMONTE V; PIANTADOSI S; HESS AD; SANTOS GW EFFECT OF THALIDOMIDE DOSE AND PLASMA-LEVEL ON PROPHYLAXIS OF ACUTE GRAFT-VERSUS-HOST DISEASE | 0 | 0 |
452 | 0 | 0 | 1122 1994 BLOOD 84(10):A335-A335 PARKER PM; NADEMANEE A; ODONNELL MR; SNYDER DS; STEIN A; SMITH E; MOLINA A; STEPAN DE; CHAO N; NILAND JC; BLUME KG; FORMAN SJ NEUTROPENIA IS A COMPLICATION OF THALIDOMIDE THERAPY FOR CHRONIC GRAFT-VERSUS-HOST DISEASE | 0 | 0 |
453 | 0 | 0 | 1123 1994 BLOOD 84(10):A431-A431 SCHLEGEL PG; FERNANDEZ LP; BAKER J; CHEN Y; CHAO NJ THALIDOMIDE DOES NOT MODULATE THE IL-2 RESPONSE OF ACTIVATED JURKAT CELLS AS MEASURED BY BETA-GAL-ACTIVITY AND BY IL-2 PRODUCTION | 1 | 1 |
454 | 6 | 25 | 1175 1995 BLOOD 86(9):3604-3609 PARKER PM; CHAO N; NADEMANEE A; ODONNELL MR; SCHMIDT GM; SNYDER DS; STEIN AS; SMITH EP; MOLINA A; STEPAN DE; KASHYAP A; PLANAS I; SPIELBERGER R; SOMLO G; MARGOLIN K; ZWINGENBERGER K; WILSMAN K; NEGRIN RS; LONG GD; NILAND JC; BLUME KG; FORMAN SJ THALIDOMIDE AS SALVAGE THERAPY FOR CHRONIC GRAFT-VERSUS-HOST DISEASE | 51 | 85 |
455 | 0 | 0 | 1176 1995 BLOOD 86(10):1577-1577 Browne PV; Wagner J; Weisdorf DJ; DeFor T; Miller WJ; Davies SM; Filipovich A; McGlave PB; Ramsay NKC; Enright H Response to thalidomide therapy in patients with refractory chronic graft-versus-host disease. | 0 | 0 |
456 | 0 | 0 | 1247 1996 BLOOD 88(10):2423-2423 Flowers MED; Tapscott SJ; Emerson J; Emerson MV; Reagan T; Taylor L; Ajer T; Siadak M; Sanders J; Zwingenberger K; Willsmann K; Appelbaum F; Sullivan KM Incidence of peripheral neuropathy (PN) prior to thalidomide treatment for chronic graft-versus-host disease (GVHD). | 0 | 0 |
457 | 0 | 0 | 1248 1996 BLOOD 88(10):2424-2424 Kulkarni S; Powles R; Mehta J; Horton C; Treleaven J; Middleton G; Eisen T; Singhal S Thalidomide for acute or chronic graft-versus-host disease. | 0 | 0 |
458 | 0 | 0 | 1315 1997 BLOOD 90(10):1673-1673 Kulkarni S; Powles R; Mehta J; Horton C; Treleaven J; Meller S; Atra A; Pinkerton CR; Singhal S Thalidomide is very effective for chronic GVHD but has no activity in acute GVHD. | 0 | 0 |
459 | 0 | 0 | 1316 1997 BLOOD 90(10):4423-4423 Mehta P; Gian VG; Smith SP; Beltz SE; Wingard JR Thalidomide is not effective for acute graft-versus-host disease. | 0 | 0 |
460 | 0 | 0 | 1412 1998 BLOOD 92(10):235B-235B Costa PT; Leaf RMLV; Morais LO; Ribeiro RA Thalidomide (TLD) and pentoxifylline (PTX) prevent the development of chronic cardiomyopathy provoked by doxorubicin (DXR) in rats without inhibiting its antitumoral effect. | 0 | 2 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
461 | 0 | 0 | 1413 1998 BLOOD 92(10):279B-279B Lim SH; Maclean R Thalidomide in IgA multiple myeloma. | 0 | 0 |
462 | 0 | 0 | 1414 1998 BLOOD 92(10):318A-318A Singhal S; Mehta J; Eddlemon P; Gray P; Cromer J; Desikan R; Ayers D; Siegel D; Munshi N; Anaissie E; Kantarjian H; Zeldis J; Barlogie B Marked anti-tumor effect from anti-angiogenesis (AA) therapy with thalidomide (T) in high risk refractory multiple myeloma (MM). | 0 | 20 |
463 | 0 | 0 | 1415 1998 BLOOD 92(10):344B-344B Kulkarni S; Powles R; Mehta J; Horton C; Treleaven J; Meller S; Atra A; Pinkerton CR; Singhal S Thalidomide in GVHD - S anti-GVHD effect separable from the antiangiogenesis? | 0 | 4 |
464 | 0 | 0 | 1499 1999 BLOOD 94(10):124A-124A Juliusson G; Celsing F; Turesson I; Adriansson M; Malm C Thalidomide frequently induces good partial remission and best response ever in patients with advanced myeloma and prior high dose melphalan and autotransplant. | 0 | 2 |
465 | 0 | 0 | 1500 1999 BLOOD 94(10):124A-124A Neben K; Hawighorst H; Moehler TM; Egerer G; Punzel M; Van Kaick G; Ho AD; Goldschmidt H Clinical response to thalidomide monotherapy correlates with improvement in dynamic magnetic resonance (d-MRI) angiogenesis parameters. | 0 | 9 |
466 | 0 | 0 | 1501 1999 BLOOD 94(10):124A-125A Moehler TM; Neben K; Egerer G; Punzel M; Schmier J; Cremer F; Goldschmidt H; Ho AD Thalidomide plus CED-chemotherapy in patients with poor prognosis multiple myeloma. | 0 | 0 |
467 | 0 | 0 | 1502 1999 BLOOD 94(10):125A-125A Shima Y; Treon SP; Yoshizaki K; Tai YT; Hideshima T; Raje N; Chauhan D; Davies F; Schlossman R; Anderson KC Clinical and biological activity of thalidomide (Thal) in multiple myeloma (MM). | 0 | 11 |
468 | 0 | 0 | 1503 1999 BLOOD 94(10):125A-125A Sabir T; Raza S; Anderson L; Jagannath S Thalidomide is effective in the treatment of recurrent. Refractory multiple myeloma (MM). | 0 | 7 |
469 | 0 | 0 | 1504 1999 BLOOD 94(10):158A-158A Koc S; Leisenring W; Flowers ME; Sullivan KM; Martin PJ Evaluation of thalidomide for the treatment of chronic graft-versus-host disease in "high risk" patients. | 0 | 1 |
470 | 0 | 0 | 1505 1999 BLOOD 94(10):308B-308B Coleman M; Gelfand RM; Leonard JP Combination non-myelosuppressive therapy (thalidomide, clarithromycin, dexamethasone) for plasma cell myeloma: A preliminary report. | 0 | 2 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
471 | 0 | 0 | 1506 1999 BLOOD 94(10):308B-308B Chen CI; Adesanya A; Sutton DM; Brandwein J; Stewart AK Low-dose thalidomide in patients with advanced, refractory multiple myeloma. | 0 | 1 |
472 | 0 | 0 | 1507 1999 BLOOD 94(10):311B-311B Kanard AM; Kane G; Thome SD; Goudreau J; Markovic SN Thalidomide associated with seizures and neuroradiologic features suggestive of reversible posterior leukoencephalopathy syndrome (RPLS) in the setting of multiple myeloma and renal failure. | 0 | 1 |
473 | 0 | 0 | 1508 1999 BLOOD 94(10):314B-315B Srkalovic G; Karam MA; McLain DA; Hussein MA Melphalan, thalidomide and decadron (MTD) for refractory/relapsed multiple myeloma (MM). | 0 | 1 |
474 | 0 | 0 | 1509 1999 BLOOD 94(10):315A-315A Cheng D; Kini AR; Rodriguez J; Burt RK; Peterson LC; Traynor AE Microvascular density and cytotoxic T cell activation correlate with response to thalidomide therapy in myeloma patients. | 0 | 8 |
475 | 0 | 0 | 1510 1999 BLOOD 94(10):316A-316A Rajkumar SV; Fonseca R; Dispenzieri A; Lacy MQ; Witzig TE; Lust JA; Kyle RA; Gertz MA; Greipp PR Thalidomide in the treatment of relapsed and refractory myeloma. | 0 | 9 |
476 | 0 | 0 | 1511 1999 BLOOD 94(10):316B-316B Wu K; Schaafsma MR; Smit WM; Neef C; Richel DJ Thalidomide as anti-angiogenesis treatment in patients with chemotherapy resistant multiple myeloma (MM). | 0 | 1 |
477 | 0 | 0 | 1512 1999 BLOOD 94(10):316A-316A Durie BGM; Stepan DE Efficacy of low dose thalidomide (T) in multiple myeloma. | 0 | 18 |
478 | 0 | 0 | 1513 1999 BLOOD 94(10):317A-317A Schiller G; Vescio R; Berenson J Thalidomide for the treatment of multiple myeloma relapsing after autologous peripheral blood progenitor cell transplant. | 0 | 8 |
479 | 0 | 0 | 1514 1999 BLOOD 94(10):317A-317A Yaccoby S; Johnson CL; Mahaffey SC; Barlogie B; Epstein J Thalidomide metabolism and its anti-myeloma efficacy in vivo. | 0 | 1 |
480 | 0 | 0 | 1515 1999 BLOOD 94(10):507A-507A Thomas DA; Aguayo A; Estey E; Albitar M; O'Brien S; Giles FJ; Beran M; Cortes J; Zeldis J; Keating MJ; Barlogie B; Kantarjian HM Thalidomide as anti-angiogenesis therapy (RX) in refractory or relapsed leukemias. | 0 | 5 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
481 | 0 | 0 | 1516 1999 BLOOD 94(10):578A-578A Munshi N; Desikan R; Anaissie E; Zangari M; Badros A; Lim S; Toor A; Morris C; Eddlemon P; Ayers D; Roberson P; Barlogie B Peripheral blood stem cell collection (PBSC) after CAD plus G-CSF as part of Total Therapy II in newly diagnosed multiple myeloma (MM): Influence of thalidomide (THAL) administration. | 0 | 7 |
482 | 0 | 0 | 1517 1999 BLOOD 94(10):603A-603A Desikan R; Munshi N; Zeldis J; Eddlemon P; Badros A; Zangari M; Singhal S; Mehta J; Ayers D; Lim S; Wilson C; Anaissie E; Crowley J; Barlogie B Activity of thalidomide (THAL) in multiple myeloma (MM) confirmed in 180 patients with advanced disease. | 0 | 3 |
483 | 0 | 0 | 1518 1999 BLOOD 94(10):604A-604A Weber DM; Gavino M; Delasalle K; Rankin K; Giralt S; Alexanian R Thalidomide alone or with dexamethasone for multiple myeloma. | 0 | 27 |
484 | 0 | 0 | 1519 1999 BLOOD 94(10):661A-661A Raza A; Lisak L; Andrews C; Little L; Muzammil M; Alvi S; Mazzoran L; Zorat F; Akber A; Ekbal M; Razvi S; Venugopal P Thalidomide produces transfusion independence in patients with long-standing refractory anemias and myelodysplastic syndromes (MDS). | 0 | 9 |
485 | 0 | 0 | 1520 1999 BLOOD 94(10):702A-702A Thomas DA; Aguayo A; Giles FJ; Albitar M; O'Brien S; Cortes J; Faderl S; Bivins C; Zeldis J; Keating MJ; Barlogie B; Kantarjian HM Thalidomide anti-angiogenesis therapy (RX) in Philadelphia (Ph)-negative myeloproliferative disorders (MPD) and myelofibrosis (MF). | 0 | 15 |
486 | 10 | 31 | 1632 2000 BLOOD 96(9):2943-2950 Hideshima T; Chauhan D; Shima Y; Raje N; Davies FE; Tai YT; Treon SP; Lin B; Schlossman RL; Richardson P; Muller G; Stirling DI; Anderson KC Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy | 89 | 172 |
487 | 0 | 0 | 1633 2000 BLOOD 96(11):146A-146A Raza A; Lisak L; Little L; Ekbal M; du Rant M; Ali E; Nascimben F; Tareen M; Venugopal P Thalidomide as a single agent or in combination with topotecan, pentoxifylline and/or Enbrel in myelodysplastic syndromes (MDS). | 0 | 6 |
488 | 0 | 0 | 1634 2000 BLOOD 96(11):146A-146A Mundle S; Zorat F; Shetty V; Allampallam K; Alvi S; Lisak L; Little L; Dean L; Nascimben F; Ekbal M; duRandt M; Broderick E; Venugopal P; Raza A Biologic determinents of clinical response to thalidomide in myelodysplasia. | 0 | 3 |
489 | 0 | 0 | 1635 2000 BLOOD 96(11):167A-167A Neben K; Moehler T; Egerer G; Kraemer A; Hillengass J; Benner A; Ho AD; Goldschmidt H High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. | 0 | 3 |
490 | 0 | 0 | 1636 2000 BLOOD 96(11):167A-167A Coleman M; Leonard JP; Nahum K; Michaeli J Non-myelosuppressive therapy with BLT-D (Biaxin (R), low dose thalidomide and dexamethasone) is highly active in Waldenstrom's macroglobulinemia and myeloma. | 0 | 10 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
491 | 0 | 0 | 1637 2000 BLOOD 96(11):167A-167A Weber DM; Rankin K; Gavino M; Delasalle K; Alexanian R Thalidomide with dexamethasone for resistant multiple myeloma. | 0 | 26 |
492 | 0 | 0 | 1638 2000 BLOOD 96(11):167A-167A Yakoub-Agha I; Attal M; Dumontet C; Moreau P; Berthou C; Lamy T; Grosbois B; Dauriac C; Dorvaux I; Bay JO; Monconduit M; Harousseau JL; Duguet C; Facon T Thalidomide in patients with advanced myeloma: Survival prognostic factors. | 0 | 11 |
493 | 0 | 0 | 1639 2000 BLOOD 96(11):168A-168A Kropff MH; Innig G; Mitterer M; Straka C; Ostermann H; Koch OM; Berdel WE; Kienast J Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (Hyper-CDT) in primary refractory or relapsed multiple myeloma. | 0 | 7 |
494 | 0 | 0 | 1640 2000 BLOOD 96(11):168A-168A Weber DM; Rankin K; Gavino M; Delasalle K; Aguayo A; Albitar M; Alexanian R Angiogenesis factors and sensitivity to thalidomide in previously untreated multiple myeloma (MM). | 0 | 10 |
495 | 0 | 0 | 1641 2000 BLOOD 96(11):168A-168A Rajkumar SV; Hayman S; Fonseca R; Dispenzieri A; Lacy MQ; Geyer S; Wellik L; Lust JA; Kyle RA; Greipp PR; Gertz MA; Witzig TE Thalidomide plus dexamethasone (Thal/Dex) and thalidomide alone (Thal) as first line therapy for newly diagnosed myeloma (MM). | 0 | 24 |
496 | 0 | 0 | 1642 2000 BLOOD 96(11):168A-169A Raza SN; Veksler Y; Sabir T; Li ZJ; Anderson L; Jagannath S Durable response to thalidomide in relapsed/refractory multiple myeloma (MM). | 0 | 7 |
497 | 0 | 0 | 1643 2000 BLOOD 96(11):232B-232B Venugopal P; Sivaraman S; Gladstone B; Jajeh A; Huang XK; Brien TO; ODonnell K; Gregory S; Preisler H Thalidomide (T) influences antigen expression on tumor cells from chronic lymphocytic leukemia. | 0 | 0 |
498 | 0 | 0 | 1644 2000 BLOOD 96(11):260B-260B Dourado CMC; Seixas-Silva JA; Besa EC Response to thalidomide in 9 patients with myelodysplastic syndromes: A promising treatment for early or post-chemotherapy in late forms of MDS. | 0 | 1 |
499 | 0 | 0 | 1645 2000 BLOOD 96(11):261B-261B Lisak LA; Little L; Dean L; Ekbal M; duRandt M; Hussain M; Kaistha V; Raza A Delayed responses to thalidomide in patients with myelodysplastic syndromes. | 0 | 0 |
500 | 0 | 0 | 1646 2000 BLOOD 96(11):266B-266B Canepa L; Ballerini F; Varaldo R; Grasso R; Clavio M; Miglino M; Pierri I; Gobbi M Myelofibrosis: Report of five cases treated with thalidomide. | 0 | 1 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
501 | 0 | 0 | 1647 2000 BLOOD 96(11):285B-285B Badros A; Zangari M; Bodenner D; Siegel E; Spoon D; Toor A; Desikan R; Arnold E; Anaissie E; Zeldis J; Tricot G; Barlogie B Hypothyroidism in patients with multiple myeloma (MM) receiving thalidomide. | 0 | 3 |
502 | 0 | 0 | 1648 2000 BLOOD 96(11):286B-286B Dimopoulos MA; Viniou N; Zomas A; Grigoraki V; Galani E; Matsouka C; Economou O; Anagnostopoulos N; Panayiotides P Treatment of Waldenstrom's macroglobulinemia with thalidomide. | 0 | 10 |
503 | 0 | 0 | 1649 2000 BLOOD 96(11):288B-288B Gibson RK; Alley L; Shuman HW Thalidomide (Thal) monotherapy is effective in previously treated recurrent multiple myeloma (MM). | 0 | 0 |
504 | 0 | 0 | 1650 2000 BLOOD 96(11):289B-289B Kakimoto T; Hattori Y; Okamoto S; Kamata T; Satoh N; Takayama N; Matsushita H; Yamada T; Du WL; Ikeda Y Thalidomide for the treatment of refractory multiple myeloma. Decreased plasma concentration of angiogenic growth factors and clinical response. | 0 | 0 |
505 | 0 | 0 | 1651 2000 BLOOD 96(11):290B-290B Linder O; Tidefelt U Thalidomide combined with dexamethasone and pamidronate to patients with advanced myeloma, better than thalidomide alone? | 0 | 0 |
506 | 0 | 0 | 1652 2000 BLOOD 96(11):290B-290B Moehler TM; Neben K; Hawighorst H; Egerer G; van Kaick G; Ho AD; Goldschmidt H Thalidomide plus CED chemotherapy as salvage therapy in poor prognosis multiple myeloma. | 0 | 5 |
507 | 0 | 0 | 1653 2000 BLOOD 96(11):290B-290B Leleu X; Cornillon J; Magro L; Guillerm G; Dalle JH; Fenaux P; Jouet JP; Bauters F; Facon T; Yakoub-Agha I Is thalidomide 50 mg/d as a minimal first dose effective in advanced myeloma? | 0 | 2 |
508 | 0 | 0 | 1654 2000 BLOOD 96(11):292B-292B Palumbo A; Giaccone L; Bertola A; Bringhen S; Rus C; Triolo S; Pileri A; Boccadoro M Thalidomide and dexamethasone as salvage therapy for refractory and relapsed myeloma. | 0 | 6 |
509 | 0 | 0 | 1655 2000 BLOOD 96(11):293B-293B Prince HM; Biagi JJ; Mitchell P; Mileshkin L; Seymour JF; Januszewicz EH; Wolf MM; Westerman DA Interferon-alpha-2b (IF) can be combined with thalidomide (Thal) in patients with multiple myeloma (MM). | 0 | 3 |
510 | 0 | 0 | 1656 2000 BLOOD 96(11):294B-294B Rodriguez J; Oyama Y; Burt RK; Traynor AE Achievement of maximal disease response to thalidomide is limited by patient tolerance more often than disease resistance. | 0 | 4 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
511 | 0 | 0 | 1657 2000 BLOOD 96(11):294B-295B Srkalovic G; Karam MA; Trebisky BM; Hussein MA Treatment of refractory/relapsed multiple myeloma (MM) with combination of melphalan, thalidomide and decadron (MTD). | 0 | 1 |
512 | 0 | 0 | 1658 2000 BLOOD 96(11):296B-296B Vescio RA; Berenson JR Thalidomide is an effective agent for patients with primary amyloidosis. | 0 | 1 |
513 | 0 | 0 | 1659 2000 BLOOD 96(11):296B-296B Zangari M; Anaissie E; Desikan R; Badros A; Morris C; Munshi N; Gopal AV; Fink L; Spoon D; Tricot G; Barlogie B Thalidomide-induced hypercoagulability in multiple myeloma (MM). | 0 | 3 |
514 | 0 | 0 | 1660 2000 BLOOD 96(11):296B-296B Tosi P; Ronconi S; Zamagni E; Cellini C; Tura S; Cavo M Salvage therapy with thalidomide for patients with advanced relapsed/refractory multiple myeloma. | 0 | 3 |
515 | 0 | 0 | 1661 2000 BLOOD 96(11):304A-304A Hideshima T; Chauhan D; Shima Y; Noopur R; Davies FE; Tai YT; Treon SP; Lin BK; Schlossman RL; Richardson PG; Gupta D; Muller GW; Stirling DI; Anderson KC Thalidomide (Thal) and its analogs overcome drug resistance of human multiple myeloma (MM) cells to conventional therapy. | 0 | 0 |
516 | 0 | 0 | 1662 2000 BLOOD 96(11):323A-323A Estey E; Albitar M; Cortes J; Giles F; Thomas D; Koller C; Beran M; Kantarjian H Addition of thalidomide(T) to chemotherapy did not increase remission rate in poor prognosis AML/MDS. | 0 | 13 |
517 | 0 | 0 | 1663 2000 BLOOD 96(11):356A-356A Alvi S; Henderson B; Shaher A; Dangerfield B; Broderick E; Jafri N; Tareen M; Du Randt M; Galili N; Borok RZ; Raza A Determination of clonality in stromal and parenchymal cells pre and post thalidomide treatment in myelodysplasia. | 0 | 0 |
518 | 0 | 0 | 1664 2000 BLOOD 96(11):359A-359A Alvi S; Shaher A; Henderson B; Dar S; Zorat F; Broderick E; Lisak L; Du Randt M; Reddy P; Mundle S; Galili N; Borok RZ; Raza A Improved growth of stromal cells in long term bone marrow cultures (LTBMC) of myelodysplastic syndrome (MDS) patients treated with thalidomide. | 0 | 1 |
519 | 0 | 0 | 1665 2000 BLOOD 96(11):364A-364A Rajkumar SV; Timm M; Mesa RA; Fonseca R; Dispenzieri A; Lacy MQ; Lust JA; Gertz MA; Kyle RA; Griepp PR; Witzig TE Effect of thalidomide on myeloma cell apoptosis and VEGF secretion. | 0 | 5 |
520 | 0 | 0 | 1666 2000 BLOOD 96(11):364A-364A Yata K; Otsuki T; Yamada O; Yawata Y Expression of angiogenic factors including VEGFs, effects of anti-VEGF-A MoAb, hypoxia, and thalidomide on myeloma cells. | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
521 | 0 | 0 | 1667 2000 BLOOD 96(11):366A-366A Petrucci MT; Ricciardi MR; Gregorj C; Palumbo G; Del Bianco P; Cartoni C; Mandelli F; Tafuri A Thalidomide effects on apoptosis in multiple myeloma: Ex-vivo and in vitro study. | 0 | 1 |
522 | 0 | 0 | 1668 2000 BLOOD 96(11):367B-367B Castro J; Talavera A; Tejeda C; Cortes L; Fradera J; Velez-Garcia E Preliminary experience of the use of thalidomide maintenance therapy after autologous transplant in patients with multiple myeloma (MM). | 0 | 0 |
523 | 0 | 0 | 1669 2000 BLOOD 96(11):368B-368B Dmoszynska A; Hus M; Legiec W; Walter-Croneck A; Wach M Delayed stem cell transplantation in patients with relapsed or refractory multiple myeloma using thalidomide as a preparative regimen. | 0 | 0 |
524 | 0 | 0 | 1670 2000 BLOOD 96(11):514A-514A Barlogie B; Spencer T; Tricot G; Zeldis J; Munshi N; Zangari M; Badros A; Toor A; Shaughnessy J; Morris C; Desikan R Long term follow up of 169 patients receiving a phase II trial of single agent thalidomide for advanced and refractory multiple myeloma (MM). | 0 | 14 |
525 | 0 | 0 | 1671 2000 BLOOD 96(11):579A-+ Lentzsch S; Podar K; Davies FE; Hideshima T; Tai YT; Chauhan D; Lin BK; Treon SP; Gupta D; Mitsiades C; Mitsiades N; Hayashi T; Muller GW; Stirling DI; Anderson KC Immunomodulatory derivatives (IMiDs) of thalidomide (Thal) inhibit the proliferation of multiple myeloma (MM) cell lines and block VEGF-induced activation of the MAPK-pathway. | 0 | 2 |
526 | 0 | 0 | 1672 2000 BLOOD 96(11):579A-+ Payvandi F; Wu L; Gupta D; Hideshima T; Haley M; Muller G; Chen R; Anderson KC; Stirling S Effects of a thalidomide analog on binding activity of transcription factors and cell cycle progression of multiple myeloma cell lines. | 0 | 1 |
527 | 0 | 0 | 1673 2000 BLOOD 96(11):579A-+ Shaughnessy J; Zhan F; Tian E; Bumm K; Muller G; Stirling D; Tricot G; Barlogie B Global gene expression analysis shows loss of c-myc and IL-6 receptor gene mRNA after exposure of myeloma to thalidomide and IMiD. | 0 | 2 |
528 | 0 | 0 | 1674 2000 BLOOD 96(11):746A-746A Piccaluga PP; Finelli C; Ricci P; Cavo M; Pileri SA; Isidori A; Malagola M; Grafone T; Tura S; Visani G Antiangiogenic therapy with thalidomide improves anemia, thrombocytopenia, hyperleucocytosis, splenomegaly in idiopathic myelofibrosis. | 0 | 4 |
529 | 0 | 0 | 1675 2000 BLOOD 96(11):746A-746A Barosi G; Grossi A; Comotti B; Marchetti M Thalidomide in patients with myelofibrosis with myeloid metaplasia. | 0 | 4 |
530 | 0 | 0 | 1676 2000 BLOOD 96(11):837A-837A Davies FE; Raje N; Hideshima T; Lentzsch S; Young G; Tai YT; Lin BK; Podar K; Chauhan D; Treon SP; Gupta D; Mitsiades C; Mitsiades N; Hayashi T; Richardson PG; Schlossman RL; Muller GW; Stirling DI; Anderson KC Thalidomide (Thal) and immunomodulatory derivatives (IMiDS) augment natural killer (NK) cell cytotoxicty in multiple myeloma (MM). | 0 | 2 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
531 | 4 | 8 | 1677 2000 BLOOD 96(12):3995-3996 Koc S; Leisenring W; Flowers MED; Anasetti C; Deeg HJ; Nash RA; Sanders JE; Witherspoon RP; Appelbaum FR; Storb R; Martin PJ Thalidomide for treatment of patients with chronic graft-versus-host disease | 14 | 23 |
532 | 1 | 3 | 1678 2000 BLOOD 96(12):4007-4007 Tefferi A; Elliott MA Serious myeloproliferative reactions associated with the use of thalidomide in myelofibrosis with myeloid metaplasia | 15 | 23 |
533 | 2 | 4 | 1828 2001 BLOOD 97(8):2527-2528 Kyrtsonis MC; Kokoris SI; Kontopidou FN; Siakantaris MP; Kittas C; Pangalis GA Development of a myeloproliferative disorder in a patient with monoclonal gammopathy of undetermined significance secreting immunoglobulin of the M class and treated with thalidomide and anti-CD20 monoclonal antibody | 0 | 1 |
534 | 9 | 18 | 1829 2001 BLOOD 98(1):210-216 Davies FE; Raje N; Hideshima T; Lentzsch S; Young G; Tai YT; Lin B; Podar K; Gupta D; Chauhan D; Treon SP; Richardson PG; Schlossman RL; Morgan GJ; Muller GW; Stirling DI; Anderson KC Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma | 48 | 91 |
535 | 9 | 21 | 1830 2001 BLOOD 98(2):492-494 Barlogie B; Desikan R; Eddlemon P; Spencer T; Zeldis J; Munshi N; Badros A; Zangari M; Anaissie E; Epstein J; Shaughnessy J; Ayers D; Spoon D; Tricot G Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients | 66 | 111 |
536 | 12 | 59 | 1831 2001 BLOOD 98(4):958-965 Raza A; Meyer P; Dutt D; Zorat F; Lisak L; Nascimben F; du Randt M; Kaspar C; Goldberg C; Loew J; Dar S; Gezer S; Venugopal P; Zeldis J Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes | 28 | 60 |
537 | 3 | 5 | 1832 2001 BLOOD 98(5):1614-1615 Zangari M; Anaissie E; Barlogie B; Badros A; Desikan R; Gopal AV; Morris C; Toor A; Siegel E; Fink L; Tricot G Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy | 59 | 90 |
538 | 0 | 0 | 1833 2001 BLOOD 98(11):52B-52B Anders O; Plath F; Emmrich J; Freund M Complete remission of therapy-resistant angiodysplasia of the stomach in myelodysplastic syndrome following thalidomide. | 0 | 0 |
539 | 0 | 0 | 1834 2001 BLOOD 98(11):52B-52B Arkel YS; Ku DHW; Le P Effect of thalidomide on tissue factor activity in monocytic and endothelial cell lines, and relationship to tumor necrosis factor-alpha (TNF). | 0 | 0 |
540 | 0 | 0 | 1835 2001 BLOOD 98(11):161A-162A Zangari M; Siegel E; Anaissie E; Saghafifar F; Morris C; Fink L; Barlogie B; Tricot G Risk factors for deep vein thrombosis (DVT) in a large group of myeloma patients (pts) treated with thalidomide (Thal): The Arkansas experience. | 0 | 4 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
541 | 0 | 0 | 1836 2001 BLOOD 98(11):162A-162A Palumbo A; Giaccone L; Bringhen S; Cavallo F; Falco P; Rus C; Bertola A; Pileri A; Boccadoro M Low dose thalidomide and dexamethasone are as effective as oral melphalan and prednisone in refractory and relapsed myeloma patients. | 0 | 4 |
542 | 0 | 0 | 1837 2001 BLOOD 98(11):162A-162A Wechalekar AD; Sutton D; Voralia M; Stewart AK; Chen CI Intermediate dose thalidomide (200mg daily) has comparable efficacy and less toxicity than higher doses in relapsed multiple myeloma. | 0 | 5 |
543 | 0 | 0 | 1838 2001 BLOOD 98(11):162A-162A Kakimoto T; Hattori Y; Okamoto S; Sato N; Yamaguchi M; Morita K; Yamada T; Takayama N; Shimada N; Tanigawara Y; Ikeda Y Clinical significance of serial monitoring of plasma concentration of thalidomide and angiogenic growth factors in patients with refractory myeloma. | 0 | 1 |
544 | 0 | 0 | 1839 2001 BLOOD 98(11):162A-163A Rajkumar SV; Dispenzieri A; Lacy M; Geyer S; Iturria N; Fonseca R; Hayman SR; Lust JA; Kyle R; Greipp PR; Gertz MA; Witzig TE Response rate and durablity of response with thalidomide therapy for relapsed multiple myeloma (MM). | 0 | 4 |
545 | 0 | 0 | 1840 2001 BLOOD 98(11):163A-163A Tosi P; Zamagni E; Cellini C; Cangini D; Tura S; Baccarani M; Cavo M Rapid response and early relapse after thalidomide plus dexamethasone salvage therapy in patients with advanced relapsed and refractor multiple myeloma. | 0 | 3 |
546 | 0 | 0 | 1841 2001 BLOOD 98(11):163A-163A Alexanian R; Weber DM; Giralt S; Delasalle KB Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy. | 0 | 2 |
547 | 0 | 0 | 1842 2001 BLOOD 98(11):163A-163A Grosbois B; Bellissant E; Moreau P; Attal M; Zerbib R Thalidomide (Thal) in the treatment of advanced multiple myeloma (MM). A prospective study of 120 patients. | 0 | 5 |
548 | 0 | 0 | 1843 2001 BLOOD 98(11):163A-163A Durie BGM; Stepan DE Low dose thalidomide alone and in combination: Long term follow-up. | 0 | 6 |
549 | 0 | 0 | 1844 2001 BLOOD 98(11):163A-163A Neben K; Moehler TM; Benner A; Kraemer A; Ho AD; Goldschmidt H Dose-dependent effect of thalidomide (Thal) on overall survival (OS) in relapsed and refractory multiple myeloma (MM). | 0 | 0 |
550 | 0 | 0 | 1845 2001 BLOOD 98(11):164A-164A Dimopoulos M; Panayiotidis P; Grigoraki V; Poziopoulos C; Xilouri I; Kiamouris C; Tassidou A; Gika D; Stefanoudaki K; Anagnostopoulos N; Anagnostou D Oral hyperfractionated cyclophosphamide and intermittent thalidomide-dexamethasone for previously treated patients with multiple myeloma. | 0 | 7 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
551 | 0 | 0 | 1846 2001 BLOOD 98(11):164A-164A Seldin DC; Choufani E; Skinner M; Wright DG; Dember L; Weisman J; Fennessey S; Finn K; Sanchorawala V A phase I/II trial of thalidomide for patients with AL amyloidosis. | 0 | 1 |
552 | 0 | 0 | 1847 2001 BLOOD 98(11):182B-182B Ural AU; Yilmaz MI; Avcu F; Pekel A; Zerman M; Yalcin A Terminal differentiation and apoptosis of myeloid leukemia induced by thalidomide and rhGM-CSF combination. | 0 | 0 |
553 | 0 | 0 | 1848 2001 BLOOD 98(11):215B-215B Manson SD; Venugopal P; Gregory SA; Raza A; Sivaraman S; Preisler H Treatment of relapsed/refractory acute myeloid leukemia (AML) with thalidomide as a single agent: Clinical and biologic responses. | 0 | 0 |
554 | 0 | 0 | 1849 2001 BLOOD 98(11):222B-222B Sivaraman S; Venugopal P; Hu WY; Gladstone B; Galili N; Nair A; Manjali J; Mogongwa A; Zhao HP; Manson S; Preisler H Effect of thalidomide as a single agent on serum cytokine levels in patients with relapsed acute myeloid leukemia. | 0 | 0 |
555 | 0 | 0 | 1850 2001 BLOOD 98(11):246B-246B Pro B; Younes A; Albitar M; Hagemeister FB; Rodriguez MA; McLaughlin P; Clemons M; Samaniego F; Cabanillas F Phase II study of thalidomide in patients with recurrent Hodgkin's disease (HD) and non-Hodgkin's lymphomas (NHL). | 0 | 0 |
556 | 0 | 0 | 1851 2001 BLOOD 98(11):271B-271B Fabbri A; Biscardi M; Innocenti F; Balestri F; Gavazzi S; Bellesi G; Grossi A Thalidomide in combination with amifostine in the treatment of MDS: Evaluation of clinical and laboratory findings. | 0 | 0 |
557 | 0 | 0 | 1852 2001 BLOOD 98(11):273B-273B Raza A; Lisak L; Dutt D; Dean L; Fantroy L; Syed E; Gezer S; Hsu WT; Goldberg C; Loew J; Venugopal P Combination of thalidomide with pentoxifylline, ciprofloxacin, and dexamethasone (PCD) in patients with myelodysplastic syndromes (MDS). | 0 | 0 |
558 | 0 | 0 | 1853 2001 BLOOD 98(11):273B-274B Raza A; Dutt D; Lisak L; Dean L; Fantroy L; Gezer S; Syed E; Goldberg C; Loew J; Hsu WT; Venugopal P Combination of thalidomide and Enbrel for the treatment of patients with myelodysplastic syndromes (MDS). | 0 | 0 |
559 | 0 | 0 | 1854 2001 BLOOD 98(11):296B-297B Dmoszynska A; Rolinski J; Bojarska-Junak A; Manko J; Jawniak D; Walter-Croneck A; Soroka-Wojtaszko M; Hus M; Domanski D Influence of thalidomide on bcl-2 expression and proangiogenic cytokine levels in short-term culture of peripheral blood and bone marrow lymphocyte subsets of multiple myeloma patients. | 0 | 0 |
560 | 0 | 0 | 1855 2001 BLOOD 98(11):307B-307B Alegre A; Macias GR; Granda A; Golbano N; Martinez E; Alaez C; Blazquez C; Gongora E; Cannata J; Sanchez-Godoy P; Martinez-Chamorro C; Arranz R; de Soria VGG; Figuera A; Arranz E; Fernandez-Ranada JM Thalidomide as rescue treatment of relapses after haematopoietic transplantation in multiple myeloma. | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
561 | 0 | 0 | 1856 2001 BLOOD 98(11):307B-307B Ahmad I; Alam AR; Hahn T; Becker J; Chanan-Khan AA; Czuczman M; Bernstein S; Bernstein Z; McCarthy P Thalidomide plus VAD (vincristine, doxorabicin and dexamethasone) salvage therapy for VAD-refractory multiple myeloma, prior to autologous peripheral blood stem cell transplant (PBSCT). | 0 | 0 |
562 | 0 | 0 | 1857 2001 BLOOD 98(11):307B-307B Bibas M; Andriani A; Ferrari A; Montanaro M; Niscola G; Recine U; Chierichini A Thalidomide treatment for relapsed/refractory multiple myeloma: A retrospective multicenter study. | 0 | 0 |
563 | 0 | 0 | 1858 2001 BLOOD 98(11):308B-308B Grosbois B; Bellissant E; Muret E; Voillat L; Zerbib R Measurement of seric thalidomide (Thal) level in patients treated for advanced multiple myeloma (MM). | 0 | 2 |
564 | 0 | 0 | 1859 2001 BLOOD 98(11):309B-309B Kasper B; Moehler TM; Neben K; Ho AD; Goldschmidt H Response to a combination therapy of thalidomide and Pegintron (R) in patients with progressive multiple myeloma (MM). | 0 | 1 |
565 | 0 | 0 | 1860 2001 BLOOD 98(11):310B-310B Mohty M; Stoppa AM; Blaise D; Isnardon D; Gastaut JA; Olive D; Gaugler B Differential regulation of dendritic cell function by the immunomodulatory drug thalidomide: Implications for multiple myeloma therapy. | 0 | 0 |
566 | 0 | 0 | 1861 2001 BLOOD 98(11):311B-311B Avalos JS; Barazzutti L; Korin J; Kusminsky G; Ferro H; Tavella O; Foncuberta M; Tartas N Thalidomide and cranial nerves neuropathies. | 0 | 0 |
567 | 0 | 0 | 1862 2001 BLOOD 98(11):311B-311B Offidani M; Mele A; Marconi M; Corvatta L; Candela M; Pieroni S; Malerba L; Rupoli S; Olivieri A; Leoni P Thalidomide plus melphalan in relapsed-refractory multiple myeloma. | 0 | 1 |
568 | 0 | 0 | 1863 2001 BLOOD 98(11):313B-313B Womeldorph JL; Myhand RC; Monahan BP Reversible acute renal failure following initiation of thalidomide therapy in a patient with relapsed multiple myeloma. | 0 | 0 |
569 | 0 | 0 | 1864 2001 BLOOD 98(11):351A-352A Alvi S; Shaher A; Shaikh M; Anthwal S; Siddiqi F; Akhtar A; Ashraf H; Meagher R; Mundle S; Shetty V; Goldberg C; Galili N; Borok RZ; Raza A MDS patients with hematological response to thalidomide show enhanced in vitro growth potential. | 0 | 0 |
570 | 0 | 0 | 1865 2001 BLOOD 98(11):352A-352A Alvi S; Shaikh M; Anthwal S; Shaher A; Tamoseviciene D; Novick A; Reddy P; Allampallam K; Hsu WT; Galili N; Borok RZ; Raza A Cytogenetic and clonal profile of myelodysplastic syndromes (MDS) patients treated with thalidomide. | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
571 | 0 | 0 | 1866 2001 BLOOD 98(11):353A-354A Baker AF; Bellamy WT; Glinsmann-Gibson BJ; Heaton R; Buresh A; Grogan TM; List AF Biological response to thalidomide in remitting patients with myelodysplastic syndrome (MDS): Evidence for induction of neoplastic vascular endothelial growth factor (VEGF) resistance. | 0 | 0 |
572 | 0 | 0 | 1867 2001 BLOOD 98(11):365B-365B Game M; Coso D; Sturgeon J; Crump M; Keating A Thalidomide and low dose vinblastine as palliative therapy for patients relapsing after autotransplant for Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL). | 0 | 1 |
573 | 0 | 0 | 1868 2001 BLOOD 98(11):373A-374A Uziel O; Shapira A; Radnay J; Lahav M; Lishner M Thalidomide downregulates transcript levels of GC-rich promoter genes in multiple myeloma. | 0 | 0 |
574 | 0 | 0 | 1869 2001 BLOOD 98(11):395B-395B Moehler TM; Neben K; Kasper B; Kordelas L; Egerer G; Goerner M; Ho AD; Goldschmidt H Thalidomide plus CED chemotherapy as remission induction regimen for poor prognosis multiple myeloma patients before autologous or allogeneic stem cell transplantation. | 0 | 0 |
575 | 0 | 0 | 1870 2001 BLOOD 98(11):622A-622A Musto P; Falcone A; Bodenizza C; Sanpaolo G; Matera R; Bisceglia M; Carella AM Thalidomide (THAL) significantly improves anemia in selected transfusion-dependent patients with myelodysplastic syndromes (MDS): Relationship to serum and marrow levels of angiogenetic growth factors (AGF). | 0 | 3 |
576 | 0 | 0 | 1871 2001 BLOOD 98(11):627A-627A Elliott MA; Mesa RA; Li CY; Hook CC; Ansell SM; Levitt R; Geyer GM; Tefferi A Thalidomide treatment in myelofibrosis with myeloid metaplasia (MMM). | 0 | 1 |
577 | 0 | 0 | 1872 2001 BLOOD 98(11):685A-685A Somlo G; Yamamoto N; Sarah C; O'Donnell M; Snyder D; Sahebi F; Kogut N; Spielberger R; Molina A; Parker P; Popplewell L; Fung H; Rodriguez R; Stein A; Krishnan A; Chow W; Lopez F; Forman S Tandem cycle high-dose melphalan and intravenous busulfan/cytoxan with peripheral blood progenitor cell rescue (PBPC) followed by interferon alpha-2 (IF) with, or without thalidomide (Thal) for multiple myeloma. High complete response rate and moderate toxicities. | 0 | 1 |
578 | 0 | 0 | 1873 2001 BLOOD 98(11):775A-775A Mitsiades N; Mitsiades CS; Poulaki V; Akiyama M; Tai YT; Lin BK; Hayashi T; Catley L; Hideshima T; Chauhan D; Treon SP; Anderson KC Apoptotic signaling induced by immunomodulatory thalidomide analogs (IMiDs) in human multiple myeloma cells: Therapeutic implications. | 0 | 1 |
579 | 0 | 0 | 1874 2001 BLOOD 98(11):775A-775A Richardson PG; Schlossman RL; Hideshima T; Davies F; LeBlanc R; Catley L; Doss D; Kelly KA; McKenney M; Mechlowicz J; Freeman A; Deocampo R; Rich R; Ryoo J; Chauhan D; Munshi N; Weller E; Thomas S; Zeldis J; Anderson KC A phase 1 study of oral CC5013, an immunomodulatory thalidomide (Thal) derivative, in patients with relapsed and refractory multiple myeloma (MM). | 0 | 10 |
580 | 0 | 0 | 1875 2001 BLOOD 98(11):849A-849A Rajkumar SV; Hayman SR; Gertz MA; Dispenzieri A; Lacy M; Greipp PR; Geyer S; Itturia N; Fonseca R; Lust JA; Kyle R; Witzig TE Combination therapy with thalidomide plus dexamethasone (THAL/DEX) for newly diagnosed myeloma (MM). | 0 | 5 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
581 | 0 | 0 | 1876 2001 BLOOD 98(11):849A-849A Neben K; Mytilineos J; Moehler TM; Preiss A; Kraemer A; Ho AD; Goldschmidt H Genetic polymorphism in the tumor necrosis factor-alpha locus influences the outcome to thalidomide therapy in relapsed and refractory multiple myeloma (MM). | 0 | 1 |
582 | 0 | 0 | 1877 2001 BLOOD 98(11):863A-863A Bennett CL; Schumok GT; Kwaan HC; Raisch DW High incidence of thalidomide-associated deep vein thrombosis and pulmonary emboli when chemotherapy is also administered. | 0 | 3 |
583 | 3 | 19 | 1878 2001 BLOOD 98(13):3846-3848 Moehler TM; Neben K; Benner A; Egerer G; Krasniqi F; Ho AD; Goldschmidt H Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy | 13 | 21 |
584 | 19 | 36 | 2053 2002 BLOOD 99(3):834-839 Steins MB; Padro T; Bieker R; Ruiz S; Kropff M; Kienast J; Kessler T; Buechner T; Berdel WE; Mesters RM Efficacy and safety of thalidomide in patients with acute myeloid leukemia | 10 | 24 |
585 | 5 | 5 | 2054 2002 BLOOD 99(11):4247-4248 Urbauer E; Kaufmann H; Nosslinger T; Raderer M; Drach J Thromboembolic events during treatment with thalidomide | 12 | 17 |
586 | 4 | 4 | 2055 2002 BLOOD 99(11):4248-4248 Lee FC Second response to lower-dose thalidomide in a patient with multiple myeloma | 2 | 2 |
587 | 3 | 6 | 2056 2002 BLOOD 99(11):4249-4249 Zangari M Thalidomide and thromboembolism - Response | 0 | 0 |
588 | 12 | 35 | 2057 2002 BLOOD 99(12):4525-4530 Mitsiades N; Mitsiades CS; Poulaki V; Chauhan D; Richardson PG; Hideshima T; Munshi NC; Treon SP; Anderson KC Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications | 13 | 53 |
589 | 4 | 23 | 2058 2002 BLOOD 100(4):1168-1171 Zangari M; Siegel E; Barlogie B; Anaissie E; Saghafifar F; Fassas A; Morris C; Fink L; Tricot G Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy | 17 | 31 |
590 | 1 | 3 | 2059 2002 BLOOD 100(4):1519-1520 Leleu X; Magro L; Fawaz A; Bauters F; Facon T; Yakoub-Agha I Efficacy of a low dose of thalidomide in advanced multiple myeloma | 7 | 7 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
591 | 4 | 20 | 2060 2002 BLOOD 100(6):2263-2265 Neben K; Mytilineos J; Moehler TM; Preiss A; Kraemer A; Ho AD; Opelz G; Goldschmidt H Polymorphisms of the tumor necrosis factor-alpha gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma | 9 | 19 |
592 | 8 | 8 | 2061 2002 BLOOD 100(6):2272-2273 Cavo M; Zamagni E; Cellini C; Tosi P; Cangini D; Cini M; Valdre L; Palareti G; Masini L; Tura S; Baccarani M Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy | 11 | 15 |
593 | 0 | 0 | 2062 2002 BLOOD 100(11):15B-15B Carneiro JDA; Garanito M; Halsman M; Matsumoto L; Odone V; del Giglio A Thalidomide as salvage therapy for acquired severe aplastice anemia (SAA) in children - Case report | 0 | 0 |
594 | 0 | 0 | 2063 2002 BLOOD 100(11):71A-71A Mesa RA; Li CY; Steensma DP; Pardanani A; Elliott MA; Kaufmann SH; Gray L; Schroeder GS; Tefferi A A combination of low dose thalidomide with prednisone in myelofibrosis with myeloid metaplasia. | 0 | 0 |
595 | 0 | 0 | 2064 2002 BLOOD 100(11):75B-75B Kaushal V; Kaushal GP; Anaissie EJ; Kurylo P; Kohli M; Fink LM; Mehta P Thalidomide-induced coagulopathy: Evidence for an indirect effect on endothelium. | 0 | 0 |
596 | 0 | 0 | 2065 2002 BLOOD 100(11):96A-96A List AF; Kurtin SE; Glinsmann-Gibson BJ; Bellamy WT; Buresh AJ; Waddleton D; Knight R High erythropoietic remitting activity of the immunomodulatory thalidomide analog, CC5013, in patients with myelodysplastic syndrome (MDS). | 0 | 3 |
597 | 0 | 0 | 2066 2002 BLOOD 100(11):96A-96A Moreno-Aspitia A; Geyer S; Li CY; Tefferi A; Witzig T; Niedrinhaus RD; Vukov AM; Morton R; Fitch T; Addo FE; Dakhil SR; Tschetter L; Colon-Otero G N998B: Multicenter phase II trial of thalidomide (Thal) in adult patients with myelodysplastic syndromes (MDS). | 0 | 1 |
598 | 0 | 0 | 2067 2002 BLOOD 100(11):105A-105A Zangari M; Barlogie B; Prather J; Eddlemon P; Anaissie E; Lee CK; Tricot G; Thertulien R; van Rhee F Marked activity also in del 13 multiple myeloma (MM) of PS 341 (PS) and subsequent thalidomide (THAL) in a setting of resistance to post-autotransplant salvage therapies. | 0 | 5 |
599 | 0 | 0 | 2068 2002 BLOOD 100(11):139A-139A List AF; Tate W; Glinsmann-Gibson BJ; Baker A The immunomodulatory thalidomide analog, CC5013, inhibits trophic response to VEGF in AML cells by abolishing cytokine-induced PI3-kinase/Akt activation. | 0 | 1 |
600 | 0 | 0 | 2069 2002 BLOOD 100(11):162A-162A Drach J; Kaufmann H; Puespoek A; Bankier A; Urbauer E; Chott A; Raderer M Marked anti-tumor activity of rituximab plus thalidomide in patients with relapsed/resistant mantle cell lymphoma. | 0 | 1 |
Page 2: 1 2 3 4 5 6 7 8 9
Generated by:
HistCite(Vlad).
Version: 2004.09.22